M&A Deal Summary |
|
|---|---|
| Date | 2020-04-29 |
| Target | Luminist Labs |
| Sector | Healthcare Services |
| Buyer(s) | DiscernDx |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2017 |
| Sector | Healthcare Services |
DiscernDx is a provider of precision medicine solutions that enables regular health monitoring, early disease detection, and personalized care for every individual, improving lives and transforming healthcare along the way. The company's mission is to empower everyone with access to individualized clinical and molecular data to proactively manage and make informed decisions about their health. DiscernDx was formed in 2017 and is based in Palo Alto, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Healthcare Services M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: California M&A | 2 of 2 |
| Country: United States M&A | 2 of 2 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-02-08 |
Applied Proteomics
San Diego, California, United States Applied Proteomics (API) is pioneering the best proteomics platform, a novel discovery approach to protein measurement-based diagnostics. API adopted an industrial approach to combine improved instrumentation, faster computing and extensive genome annotations with regimented standard operating procedures, extensive quality controls, and documented processes spanning hundreds of steps from sample collection to processing through informatics. |
Buy | $2M |
